Technical Analysis for BMRN - BioMarin Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade F 77.33 -2.42% -1.92
BMRN closed down 2.42 percent on Monday, October 19, 2020, on 44 percent of normal volume.
Earnings due: Oct 21
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical BMRN trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
Crossed Above 20 DMA Bullish -2.42%
Bollinger Band Squeeze Range Contraction -2.42%
Multiple of Ten Bearish Other -2.42%
Fell Below 20 DMA Bearish -0.44%
Stochastic Sell Signal Bearish -0.44%
Bollinger Band Squeeze Range Contraction -0.44%
Doji - Bullish? Reversal -0.44%
Older End-of-Day Gignals for BMRN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 5 hours ago
Fell Below Previous Day's Low about 5 hours ago
Fell Below 20 DMA about 5 hours ago
60 Minute Opening Range Breakdown about 7 hours ago
10 DMA Support about 9 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Medicine Health Cancer Treatment Of Cancer Drug Discovery Rare Diseases Virotherapy Serious Diseases Autoimmune Disease Biopharmaceuticals Inborn Errors Of Metabolism Enzyme Replacement Therapy Phenylketonuria Pharmaceutical Wholesalers Pku Pompe Disease Achondroplasia Biomarin Pharmaceutical Genetic Disease Iduronidase Intellectual Disability Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Novato

Is BMRN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 131.945
52 Week Low 67.1
Average Volume 2,754,373
200-Day Moving Average 94.61
50-Day Moving Average 82.40
20-Day Moving Average 77.74
10-Day Moving Average 78.53
Average True Range 2.56
ADX 23.34
+DI 18.79
-DI 26.12
Chandelier Exit (Long, 3 ATRs ) 73.25
Chandelier Exit (Short, 3 ATRs ) 81.49
Upper Bollinger Band 80.63
Lower Bollinger Band 74.86
Percent B (%b) 0.43
BandWidth 7.42
MACD Line -0.97
MACD Signal Line -1.65
MACD Histogram 0.6762
Fundamentals Value
Market Cap 14.02 Billion
Num Shares 181 Million
EPS 0.68
Price-to-Earnings (P/E) Ratio 114.39
Price-to-Sales 7.76
Price-to-Book 4.42
PEG Ratio 0.84
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 82.09
Resistance 3 (R3) 82.49 81.30 81.29
Resistance 2 (R2) 81.30 80.09 81.10 81.03
Resistance 1 (R1) 79.32 79.34 78.73 78.92 80.76
Pivot Point 78.13 78.13 77.84 77.93 78.13
Support 1 (S1) 76.15 76.92 75.56 75.75 73.90
Support 2 (S2) 74.96 76.17 74.76 73.63
Support 3 (S3) 72.98 74.96 73.37
Support 4 (S4) 72.58